Iryna Drozd
T2 Biosystems (NASDAQ:TTOO) has received breakthrough device status from the US Food and Drug Administration for its Candida auris molecular diagnostic blood test.
The test is designed to detect C. auris, a multi-drug resistant fungal pathogen, in three to five hours, without the need to wait days for a blood culture, T2 Biosystems said.
More on T2 Biosystems:
T2 Biosystems reports Q2 revenue and FY23 guidance
T2 Biosystems stock soars on conversion of 20% of CRG term loan into equity
T2 Biosystems seeks FDA breakthrough designation for C. auris test
